Last reviewed · How we verify
Lenvatinib and Sorafenib
Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases.
Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases. Used for RCC (Renal Cell Carcinoma).
At a glance
| Generic name | Lenvatinib and Sorafenib |
|---|---|
| Sponsor | Stephen Chan Lam |
| Drug class | Multi-kinase inhibitor |
| Target | VEGFR, PDGFR, FGFR, and other kinases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Lenvatinib and Sorafenib are both multi-kinase inhibitors that work by blocking the activity of certain enzymes (kinases) involved in the growth and spread of cancer cells.
Approved indications
- RCC (Renal Cell Carcinoma)
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Weight loss
Key clinical trials
- Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy (PHASE2)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (PHASE3)
- Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (PHASE3)
- Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. (PHASE2)
- A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lenvatinib and Sorafenib CI brief — competitive landscape report
- Lenvatinib and Sorafenib updates RSS · CI watch RSS
- Stephen Chan Lam portfolio CI